Optimized anti-CD30 antibodies
US9574006B2 · kind B2 · utility
4Cited by
52References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2011 |
| Grant date | Feb 21, 2017 |
| Priority date | — |
| Expiry date | Jun 17, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.